Research programme: therapeutic agents - Relivia

Drug Profile

Research programme: therapeutic agents - Relivia

Alternative Names: RLV 028; RLV 210; RLV 218; RLV-028 (furpalmate back-up); RLV-210 [UL-OHA]; RLV-218 [OHA-OAL]; RLV-C21 (deferiprone); RLV-C94 (deferiprone back-up)

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Relivia
  • Class
  • Mechanism of Action Chelating agents; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Iron overload; Skin disorders; Vascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-disorders in Italy (Topical)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-disorders in Italy (Topical)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Iron-overload in Italy (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top